^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review

Published date:
08/19/2022
Excerpt:
...we first report a previously treated advanced lung adenocarcinoma patient with de novo SND1-BRAF fusion who achieves partial response to the MAK inhibitor trametinib.
DOI:
https://doi.org/10.3389/fonc.2022.945620